TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Summary

The investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the role of this treatment in modulating the systemic inflammatory response and its potential impact on 90- and 180-day morbidity and mortality and neurological outcomes.

Conditions

• Cardiac Arrest (CA)
• Post Cardiac Arrest Syndrome

Interventions

DRUG

Infliximab

The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name "anbaite".The dosage was administered at 5 mg/kg, dissolved in 250 mL of 0.9% sodium chloride injection, and delivered via intravenous infusion over 2 hours.

DRUG

Sodium chloride injection USP, 0.9% (placebo)

Patients in the control group received 250 mL of 0.9% sodium chloride injection as a placebo, administered via intravenous infusion over 2 hours.

Sponsors & Collaborators

• Peking University First Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Peking University Shenzhen Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Jiangsu Provincial People's Hospital

  collaborator OTHER

• Hunan Provincial People's Hospital

  collaborator OTHER

• Sichuan Provincial People's Hospital

  collaborator OTHER

• People's Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• People's Hospital of Xinjiang Uygur Autonomous Region

  collaborator OTHER

• Renmin Hospital of Wuhan University

  collaborator OTHER

• Peking University Third Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-10-01

Primary Completion

2028-07-31

Completion

2028-10-31